Jim Scopa
Director/Board Member at ALIGOS THERAPEUTICS, INC.
Net worth: 246 789 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lawrence Blatt | M | 62 | 6 years | |
| Laurent Fischer | M | 60 | 4 years | |
| Richard Scheller | M | 70 |
DICE Molecules SV, Inc.
 DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 9 years |
| Clarence Machado | M | 60 | 7 years | |
| Paul H. McPherson | M | - |
Astute Medical, Inc.
 Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | 17 years |
| Peter Soparkar | M | 53 | 5 years | |
| Sharon Tetlow | F | 64 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 years |
| Jake Simson | M | 38 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 years |
| Shaan Gandhi | M | 38 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 years |
| Stephen Zachary | M | 42 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 5 years |
| Bridget Martell | M | 58 | 3 years | |
| Vaseem Mahboob | M | 55 | 8 years | |
| Rabia Ozden | M | 56 | 2 years | |
| Scott Whitcup | M | 64 | 4 years | |
| Jordyn Tarazi | F | - | - | |
| Reed Tuckson | M | 73 | 3 years | |
| Lucinda Quan | F | 51 | 6 years | |
| Heikki Jouttijärvi | M | - | 4 years | |
| Soo Hong | F | 52 | 2 years | |
| Anand Reddi | M | 42 | - | |
| Michael Thompson | M | - | 1 years | |
| Philip Johnson | M | 59 | 1 years | |
| Dawn Svoronos | F | 70 | 4 years | |
| Carole Nüchterlein | F | 62 | 6 years | |
| C. Nicholson | M | 68 | 1 years | |
| K. Hirth | M | 72 | 6 years | |
| J. Judice | M | 61 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 11 years |
| John Rakow | M | 67 | 3 years | |
| Mark Lupher | M | 53 | 5 years | |
| Nancy E. Stagliano | M | 57 |
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | 5 years |
| Linda Rubinstein | F | 58 | 2 years | |
| W. Todd Myers | M | 56 |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | - |
| Bill Tan | M | - | 3 years | |
| Edward Hurwitz | M | 60 |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 7 years |
| James Blair | M | 84 |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | - |
| Kristina Engeseth | F | - | - | |
| Gordon Brooks | M | - | 1 years | |
| Star Seyedkazemi | M | 50 | 2 years | |
| Sushmita M. Chanda | M | 58 | 6 years | |
| Julian Symons | M | 63 | 6 years | |
| Romuald Corbau | M | 55 | - | |
| Elizabeth Stoner | M | 73 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 17 years |
| Carla Fiankan | F | - | - | |
| Dena House | F | - | 5 years | |
| Kim Blickenstaff | M | 71 |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | - |
| Fred J. Dotzler | M | 78 |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | - |
| Briggs Morrison | M | 65 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 9 years |
| David L. Douglass | M | - |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | - |
| R. Ramelmeier | M | 62 | 1 years | |
| Patrick Baeuerle | M | 66 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 9 years |
| Lesley Calhoun | F | 58 | 4 years | |
| Karin A. Hughes | M | - |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | - |
| Mark Timney | M | 58 |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | 4 years |
| Greg Sieczkiewicz | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 9 years |
| Raidy Kevin J. | M | 55 |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | - |
| Chris Anderson | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leone Patterson | F | 61 | 5 years | |
| Paul Cleveland | M | 67 | 4 years | |
| Thomas Woiwode | M | 52 | 7 years | |
| Wendye Robbins | M | 63 |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | 7 years |
| Christopher J. DeRespino | M | 43 | - | |
| John D. McDermott | M | 63 | - | |
| Scott Robertson | M | 44 | 7 years | |
| Mitchell Finer | M | 65 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 13 years |
| Jack Nielsen | M | 60 | 6 years | |
| Christopher G. Chavez | M | 68 | 4 years | |
| Keith Marshall | M | 56 | 3 years | |
| Jennifer Cheng | M | 51 | 4 years | |
| Mehdi Gasmi | M | 57 | 6 years | |
| John W. Vander Vort | M | 59 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | - |
| Kimberley Elting | F | 59 | 3 years | |
| Shinichiro Fuse | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 5 years |
| Shari L. O'Quinn | F | 50 | 7 years | |
| Mittie Doyle | M | 59 | 1 years | |
| Lisa Coca | F | 55 |
Deutsche Bank Corp.
 Deutsche Bank Corp. Regional BanksFinance Part of Deutsche Bank AG, Deutsche Bank Corp. is a company based in New York, NY. | 3 years |
| Rekha Hemrajani | F | 54 | 2 years | |
| Lisa Westley | F | - |
Thomas Weisel Partners LLC
 Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | 4 years |
| Angela Thedinga | F | 42 | 2 years | |
| Myesha Lacy | F | - | - | |
| Lisa Bowers | F | 51 | 1 years | |
| John Jacobsen | M | 56 | 8 years | |
| Vivek K. Jayaraman | M | 49 | 7 years | |
| Roger Ehrenberg | M | 59 |
Deutsche Bank Corp.
Deutsche Bank Corp. Regional BanksFinance Part of Deutsche Bank AG, Deutsche Bank Corp. is a company based in New York, NY. | 4 years |
| Preston Klassen | M | 55 | 6 years | |
| Frank Baldino | M | 71 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | - |
| Ashley L. Dombkowski | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 11 years |
| Jack Anthony Thrift | M | 58 | - | |
| Eric Carter | M | 72 | 4 years | |
| Anthony Adam Rosenberg | M | 71 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 5 years |
| Dan Kisner | M | 77 | - | |
| Alan C. Mendelson | M | 76 |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | - |
| David Stack | M | 72 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 12 years |
| Ken Greenberg | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 3 years |
| Jake Nunn | M | 53 | 8 years | |
| Doug Roeder | M | 53 | 8 years | |
| Ryan Drant | M | 53 | 6 years | |
| Jennifer Giottonini Cayer | F | - | 7 years | |
| Marc Olivier Perret | M | 65 | 7 years | |
| Leonid Beigelman | M | 66 | 5 years | |
| Rupert D’Souza | M | 65 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jim Scopa
- Personal Network
